Latest News

Under the agreement, Lilly will obtain exclusive worldwide rights, excluding South Korea, to develop, manufacture, and commercialise sonefpeglutide, a long-acting GLP-2 analogue.

The regulatory decision follows results from a Phase Ib study presented at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference and the 2026 International Scientific Congress on SMA Europe.

Under the agreement, Servier will take control of Edgewise Therapeutics’ muscular dystrophy portfolio, including its lead candidate sevasemten.

The newly cleared technology aims to standardize routine ultrasound examinations, reduce variability between operators, and minimize the need for repeat scans.

The partnership introduces a new model of care that combines advanced remote monitoring, post-discharge support, and hospital-at-home services, allowing patients to remain connected to healthcare professionals throughout their recovery journey.

The at-home model integrates medical-grade care into everyday living, allowing patients to receive treatment in a private environment while still benefiting from hospital-level standards.

The initiative focuses on expanding genomic sequencing capacity, improving molecular diagnostics, and enhancing real-time disease surveillance across African health systems.

The financing will also reinforce critical pillars of outbreak control, including disease surveillance, laboratory diagnostics, infection prevention and control, and cross-border coordination mechanisms.

The plan targets key pillars of outbreak control, including emergency coordination, disease surveillance, laboratory diagnostics, infection prevention and control, and clinical case management.

Under the new framework, Arcera Life Sciences will collaborate with M42 to harness genomics data and explore disease prevalence patterns across targeted genetic and rare conditions.